Lv3
303 积分 2021-07-29 加入
A multiregional, randomized, controlled, open-label, phase 3 study of the anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Trial in progress
5小时前
已完结
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
5个月前
已完结
Trends in target novelty in oncology R&D
5个月前
已关闭
Trends in target novelty in oncology R&D
5个月前
已完结
Claudin 18.2 as a novel therapeutic target
6个月前
已完结
Gastric cancer
8个月前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
8个月前
已完结
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
10个月前
已完结
皖公网安备34019202002308
